Allakos Inc.: management transactions · United States · SEC (Form 4)

About Allakos Inc.

Allakos Inc. is a United States-based biotechnology company listed on the Nasdaq market. Founded in March 2012 and incorporated in Delaware, the company has focused on discovering and developing antibodies for allergic, inflammatory and proliferative diseases. Its historical operating base has been in San Carlos, California, although recent SEC filings show that the company has materially reduced its real-estate footprint as part of a broad restructuring. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1564824/000119312518214117/d447521ds1a.htm?utm_source=openai)) Allakos built its pipeline around precision-immunology concepts aimed at blocking immune pathways involved in allergy and inflammation. The company’s lead asset for several years was lirentelimab (AK002), which was pursued in indications linked to eosinophil- and mast-cell-driven disease. After disappointing clinical outcomes across key programs, Allakos shifted its emphasis to AK006, another antibody candidate intended to address related inflammatory disease pathways. In January 2024, the company announced a restructuring to cut costs and concentrate on AK006 and select preclinical programs. ([nasdaq.com](https://www.nasdaq.com/press-release/allakos-provides-business-update-and-reports-fourth-quarter-and-full-year-2021?utm_source=openai)) That strategy was effectively unwound in early 2025. Following weak Phase 1 results for AK006, Allakos announced in January 2025 that it would discontinue further development of AK006, reduce its workforce by about 75%, and pursue strategic alternatives designed to maximize shareholder value, including a merger, sale, asset divestiture, licensing transaction, or other strategic deal. SEC filings in 2025 also make clear that the company has not generated revenue to date and continues to report significant losses, underscoring the high-risk, event-driven nature of the equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm?utm_source=openai)) From a competitive standpoint, Allakos operates in a highly crowded biotechnology landscape dominated by larger companies with stronger development, regulatory and commercial capabilities. The investment case therefore depends less on traditional operating scale and more on scientific execution, financing flexibility, and the outcome of the company’s strategic review. For international investors, especially in France, Belgium and Switzerland, ALLK on Nasdaq represents a classic U.S. small-cap biotech situation: limited operating leverage, no commercial revenue, heavy dependence on clinical data, and a meaningful possibility that value creation now comes from corporate action rather than from pipeline expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1564824/000095017025065604/allk-20250331.htm?utm_source=openai))